Inflammasome activation and pulmonary viral loads define two distinct clinical outcomes in COVID-19.

- Keyla S.G. de Sá¹, Luana A. Amaral¹, Camila C.S. Caetano¹, Amanda 5
- Becerra¹, Sabrina S. Batah², Isadora M. de Oliveira¹, Letícia S. Lopes¹, Leticia 6
- Almeida¹, Samuel Oliveira¹, Danilo Tadao Wada³, Marcel Koenigkam-Santos³, 7
- Ronaldo B. Martins¹, Roberta R. C. Rosales¹, Eurico Arruda¹, Alexandre T 8
- Fabro², Dario S. Zamboni^{1*}. 9
- ¹Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos. 11
- Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão 12
- 13 Preto, SP, 14049-900, Brazil.
- 14 ²Departamento de Patologia e Medicina Legal, Faculdade de Medicina de
- Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, 14049-900, 15
- Brazil. 16

20

23

1

2

3

4

- 17 ³Departamento de Imagens Médicas, Hematologia e Oncologia, Faculdade de
- Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, 18
- 14049-900, Brazil. 19
- 21 *Correspondence:
- Email: dszamboni@fmrp.usp.br 22

Abstract

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

COVID-19 has affected more than half a billion people worldwide, with more than 6.3 million deaths, but the pathophysiological mechanisms involved in lethal cases and the host determinants that determine the different clinical outcomes are still unclear. In this study, we assessed lung autopsies of 47 COVID-19 patients and examined the inflammatory profiles, viral loads, and inflammasome activation. Additionally, we correlated these factors with the patient's clinical and histopathological conditions. Robust inflammasome activation, mediated by macrophages and endothelial cells, was detected in the lungs of lethal cases of SARS-CoV-2. An analysis of gene expression allowed for the classification of COVID-19 patients into two different clusters. Cluster 1 died with higher viral loads and exhibited a reduced inflammatory profile than Cluster 2. Illness time, mechanical ventilation time, pulmonary fibrosis, respiratory functions, histopathological status, thrombosis, viral loads and inflammasome activation significantly differed between the two clusters. Our data demonstrated two distinct profiles in lethal cases of COVID-19, thus indicating that the balance of viral replication and inflammasome-mediated pulmonary inflammation led to different clinical outcomes. We provide important information to understand clinical variations in severe COVID-19, a process that is critical for decisions between immune-mediated or antiviral-mediated therapies for the treatment of critical cases of COVID-19.

Introduction

46

47

After the COVID-19 pandemic, coronaviruses became frequent viral agents of 48 acute respiratory distress syndrome (ARDS). Between 2019 and 2021, there 49 were more than 255,000,000 confirmed cases and 5,127,000 deaths caused by 50 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide 51 (WHO, 2020). Severe ARDS is characterized by major pulmonary involvement, 52 respiratory distress, systemic thrombosis, and death (Batah and Fabro, 2021; 53 Bösmüller et al., 2021; Polak et al., 2020). The activation of the NLRP3 54 inflammasome has been described in response to SARS-CoV-2 infections 55 56 (Cama et al., 2021; Eisfeld et al., 2021; Junqueira et al., 2022; Lucas, 2020; Rodrigues et al., 2021; Sefik et al., 2022), and this process contributes to 57 58 excessive inflammation and poor clinical outcome. The recruitment of immune cells to the lungs of infected individuals culminates in the excessive release of 59 60 cytokines that cause structural damage to the lungs (Kommoss et al., 2020; Xu et al., 2020). Moreover, the major reported lung pathologies of severe COVID-61 62 19 include diffuse alveolar damage (DAD), acute fibrinoid organizing pneumonia (AFOP), and chronic interstitial pneumonia (Batah and Fabro, 2021; Bösmüller 63 et al., 2021; Polak et al., 2020; Sauter et al., 2020). NLRP3 inflammasome 64 activation also occurs in the lung parenchyma of these patients (Rodrigues et 65 al., 2021; Toldo et al., 2021). However, it is still unknown how inflammasome 66 activation promotes the exacerbated inflammatory process during SARS-CoV-2 67 infection and how it impacts viral replication and the development of important 68 clinical characteristics associated with death in COVID-19 patients. In the 69 present study, postmortem lung tissue samples from 47 fatal COVID-19 patients 70 were examined for inflammasome activation and gene expression; in addition, 71 72 these factors were correlated with the clinical conditions of the patients to understand the molecular mechanisms underlying the pathological processes 73 that lead to the death of these patients. We demonstrated the presence of 74 robust inflammasome activation in the lungs of patients infected with SARS-75 CoV-2 and defined the specific cell types that contribute most to inflammasome 76 activation. An analysis of gene expression in pulmonary tissues allowed for the 77 classification of COVID-19 patients into two different clusters: one cluster with 78

patients who died with higher viral loads and reduced inflammatory profiles, which opposes the data from the other cluster. Our data establish that the magnitude of inflammasome activation contributes to the pathology of COVID-19 by balancing a thrombotic versus a fibrotic process that impacts the clinical outcome of the disease and patient death.

Results

79

80

81

82

83

84

85

86

87

88

89

Lethal cases of COVID-19 develop severe acute respiratory distress syndrome (ARDS) and higher inflammasome activation.

We evaluated inflammasome activation in the lung parenchyma of 47 patients 90 who died from SARS-CoV-2 infection from April to July 2020. These patients 91 were infected with the ancestral strain of SARS-CoV-2 before the development 92 93 of the COVID-19 variants of concern and before the use of vaccinations. As noninfected controls, we evaluated inflammasome activation in biopsies of the 94 95 benign area of the lungs from patients who died due to lung adenocarcinoma (referred as uninfected controls). The data in **Table 1** show the demographic 96 and clinical characteristics of the 47 patients. As reported in the early COVID-19 97 cases (that occurred in 2020), we found a high frequency of comorbidities, such 98 as hypertension, obesity, diabetes, heart and lung disease. Furthermore, the 99 patients exhibited altered values of CRP, D-dimers, LDH, creatinine, urea, AST, 100 ALT, PT (INR), and blood glucose levels. The patients had an average illness 101 time of 18 days, and the majority of the patients (76.59%) used MV, with an 102 average of 12.38 days of use of mechanical ventilation. The patients had 103 considerably altered PaO₂ and PaO₂/FiO₂ characterizing a moderate to severe 104 ARDS condition and consistent with the respiratory statuses. The 105 histopathological analyses of COVID-19 patients demonstrated a high fibrotic 106 phase of DAD, OP, and pneumonitis (**Table 1**). To analyze the histological 107 108 features of patients' lungs, we measured the lung parenchyma area in the histological sections to assess loss of airspace. In support of the data described 109 above, we observed that COVID-19 patients had a higher parenchyma area 110

111 (loss of airspace), suggesting that SARS-CoV-2 triggers robust inflammatory infiltration to the lung in severe cases of the disease (Supplementary Fig. 1A-112 C). These data are in agreement with histopathological findings showing an 113 intense inflammatory process in patients who died from SARS-CoV-2 (Batah 114 and Fabro, 2021; Hariri et al., 2021). To assess inflammasome activation in the 115 116 lungs of COVID-19 patients, the lung parenchyma area and cell count were scanned in histological sections by using multiphoton microscopy. The 117 parenchyma area was calculated by using ImageJ software, and inflammasome 118 119 activation was microscopically scored by the presence of characteristic NLRP3 120 or ASC puncta/specks (Hauenstein et al., 2015). The parenchyma area was 121 used to normalize all of the counts between the patients. Inflammasome 122 activation was quantified by counting ASC and NLRP3 puncta in the lung tissue of these patients. We observed that patients with SARS-CoV-2 infection had 123 124 robust inflammasome activation, as shown by the abundant presence of ASC 125 and NLRP3 puncta in the lungs (**Supplementary Fig. 1D-G**). Representative images of ASC and NLRP3 puncta in the patients' lungs are shown 126 127 (Supplementary Fig. 1E, G). Importantly, we observed ASC colocalization in nearly all of the scored NLRP3 puncta, thus confirming that these puncta 128 structures that were abundantly found in the patient's lungs are indeed the 129 NLRP3/ASC inflammasome (Supplementary Fig. 1H, I). Collectively, these 130 data indicate that COVID-19 patients have high inflammasome activation and 131 that these patients evolved to a fibrotic phase of DAD, OP, and pneumonitis. 132 133 Macrophages and endothelial cells contribute to inflammasome activation 134 in lethal cases of COVID-19. 135 136 To comprehensively investigate the cell types operating during SARS-CoV-2 137 infection, we aimed to assess which cell types promote inflammasome 138 activation in the lung of COVID-19 patients. We found abundant ASC and 139 NLRP3 puncta in macrophages (CD64⁺), endothelial cells (CD34⁺), type 1 140 pneumocytes (PDPN⁺), and type 2 pneumocytes (SFTPC⁺) (**Figure 1A-H**). We 141 scored ASC and NLRP3 puncta in CD64+, CD34+, PDPN+, and SFTPC+ and 142 compared them with uninfected controls. We observed that in the lungs of 143

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

COVID-19 patients, both ASC and NLRP3 puncta were significantly higher in macrophages (Figure 1I, M) and endothelial cells (Figure 1J, N) than in controls. In contrast, in the assessment of type 1 and type 2 pneumocytes, we found that ASC and NLRP3 puncta did not differ from uninfected controls, suggesting that these cells contribute less to overall inflammasome activation (Figure 1K, L, O, P). Analyzing the total numbers of macrophages, endothelial cells, type 1 pneumocytes, and type 2 pneumocytes in the lungs of patients who died from SARS-CoV-2 infection, we did not find differences in total counts of these cell types comparing COVID-19 and uninfected controls (Supplementary Fig. 2A-D). Together, these data demonstrate the main contribution of macrophages and endothelial cells but not pneumocytes, to inflammasome activation during SARS-CoV-2 infection. Subsequently, we performed immunohistochemistry analyses of the lung parenchyma to assess the expression of inflammasome components and observed variable expression of NLRP3, ASC, cleaved GSDMD, IL-1ß, and caspase-1 in COVID-19 patients (Supplementary Fig. 3A-E). To assess which lung parenchyma cells expressed these inflammasome components, we used immunohistochemistry to evaluate the expression of ASC, NLRP3, caspase-1, cleaved GSDMD, and IL-1β on macrophages, endothelial cells, and type 2 pneumocytes. We also stained these tissues with anti-Spike of SARS-CoV-2 and found that virus-associated endothelial cells, macrophages, and type 2 pneumocytes expressed ASC, NLRP3, Caspase-1, and IL-1β (Supplementary Fig. 3F-H). Disease progression in fatal cases of COVID-19 occurs with decreasing viral load and increasing inflammasome activation. To assess whether inflammasome activation was associated with specific patient clinical conditions, we performed Pearson's correlations in COVID-19 patients. Even though all of these patients died, we observed a strong negative correlation between viral load and the time of the disease (symptoms onset to

176 death) (Figure 2A, B). In addition, we observed a positive correlation between the amount of NLRP3 and ASC puncta with the time of disease (Figure 2C, D), 177 thus suggesting that, in general, whereas the viral load is reduced. 178 inflammasome activation increases during hospitalization in these lethal cases 179 of COVID-19. We also observed significant negative correlations between 180 181 NLRP3 puncta and PaO₂/FiO₂ (**Figure 2E**), suggesting that inflammasome activation is related to an overall worsening pulmonary function. We detected no 182 183 statistically significant correlations between NLRP3 or ASC puncta and viral load in the tissues (Supplementary Fig. 4). 184 185 Inflammasome activation and pulmonary viral loads define two distinct 186 clinical outcomes in lethal cases of COVID-19. 187 188 The imbalance of inflammatory and anti-inflammatory processes leads to an 189 190 excessive release of cytokines into the systemic circulation with potentially deleterious consequences, including systemic inflammatory response syndrome 191 192 (SIRS), circulatory shock, multiorgan dysfunction syndrome (MODS), and death 193 (Sinha et al., 2020). Several studies have reported the association of SARS-CoV-2 with hyperinflammatory syndrome related to disease severity (Chen et 194 al., 2021; Huang et al., 2005; Qin et al., 2020), and inflammasome activation 195 196 may be associated with Cytokine Release Syndrome (CRS) (Cui and Zhang, 2020; Dolinay et al., 2012; Olajide et al., 2021). Thus, to correlate 197 inflammasome activation with the hyperinflammatory profile observed in lethal 198 cases of COVID-19, we analyzed the expression of genes related to the 199 inflammatory process and inflammasome activation. We evaluated gene 200 201 expression in the lungs of COVID-19 patients and observed that several 202 inflammatory cytokine genes positively correlate with genes involved in inflammasome activation (Supplementary Fig. 5A). We did not observe a 203 significant difference in the expression of these genes when we compared 204 COVID-19 patients with uninfected controls (Supplementary Fig. 5B-U), 205 possibly due to the large dispersion of data observed in COVID-19 patients. 206 Due to this dispersion and high variation in gene expression detected in COVID-207 19 patients, we performed an unsupervised heatmap constructed with data from 208

210

211

212

213

214

215

216217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

relative gene expression and revealed the formation of two clusters in COVID-19 patients (Figure 3). Cluster 1 was characterized by a higher viral load and lower expression of inflammasome and inflammatory genes. In contrast to Cluster 1, Cluster 2 was comprised of patients who died with a lower viral load and increased expression of inflammasome and inflammatory genes (Figure **3A**). To gain insights into key differences between these two clusters, we analyzed PaO₂/FiO₂ and A-a O₂ gradient kinetics in these patients. We observed that patients in Cluster 2, who had overall increased inflammation, had worsening pulmonary function compared to those in Cluster 1 (Figure 3B, **C**). Basic demographic information stratified by cluster is provided in **Table 2**. Strikingly, patients who belonged to Cluster 2 had a long illness time (Figure **3D**), worse pulmonary function (as indicated by the PaO₂/FiO₂ and A-a O₂ gradients) (Figure 3E, F), greater inflammasome activation, as measured by NLRP3 puncta formation (Figure 3G), and increased area of pulmonary parenchyma, indicating loss or airways (Figure 3H). Images of the lung parenchyma of three representative patients from each cluster are shown (Figure 3I-J). Importantly, we found that patients belonging to Cluster 2 had an overall lower viral load than patients from Cluster 1; this was quantified both by RT-PCR for N2 and E gene expression (Figure 4A, B), and by expression of Spike protein (Figure 4C-E). Next, we assessed radiological analyses of 15 patients from Cluster 1 and 31 patients from Cluster 2 by comparing the first and last chest X-ray images (CXR) and observed overall worsening pulmonary conditions in patients from Cluster 2 (Supplementary Fig. 6A). Representative images of CXR of two patients from Cluster 1, with Mild/Moderate pneumonia (stable conditions) (**Supplementary Fig. 6B**) and two patients from Cluster 2 with severe pneumonia (worsening) are shown (Supplementary Fig. 6C). **Table 3** summarizes the general imaging evaluation findings for the patients in Cluster 1 and Cluster 2. Taken together, our data suggest the existence of two distinct groups of patients who succumbed to COVID-19, one group with lower viral loads, higher inflammation, and worse pulmonary conditions than the other group.

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260 261

262

263

264

265

266

267

268

269

270

271

272

273

Differential regulation of fibrinolysis-related genes and growth factors dictate the induction of fibrosis or disseminated intravascular coagulation in fatal cases of COVID-19. Histopathological analyses of the lungs from lethal cases of COVID-19 belonging to Clusters 1 and 2 allowed us to detect an increased development of fibrosis in patients from Cluster 2 (Figure 5A, and Table 2). By contrast, patients belonging to Cluster 1 exhibited a markedly increased disseminated intravascular coagulation (Figure 5B, and Table 2), according to the parameters recommended by the International Society of Thrombosis and Hemostasis (ISTH) (Taylor et al., 2001). In support of our analyses demonstrating increased disseminated intravascular coagulation, we found reduced platelet counts in patients from Cluster 1 (Figure 5C, and Table 2), supporting that vascular dysfunctions impact clinical outcomes in patients belonging to Cluster 1. To further investigate the biological pathways involved in the induction of fibrosis in Cluster 2 patients, we assessed the expression of fibrosis-related genes in the patient's lungs. We observed an increased expression of genes related to fibrinolysis, inflammatory cytokines, nitric oxide-induced, extracellular matrix deposition, and extracellular matrix remodeling in patients belonging to Cluster 2 (Figure 5D). A volcano plot indicates genes differentially expressed in samples from Cluster 2 compared to Cluster 1, including Pla (Figure 5E), Plat (Figure 5F), Plau (Figure 5G); Ccr2 (Figure 5H), Ccl3 (Figure 5I); Cdkna1 (Figure 5J); Serpina1 (Figure 5K), Timp2 (Figure 5L) and Fgf1 (Figure 5M). To further illustrate the differences between fibrosis and thrombosis in patients from these different clusters, we performed Masson-Goldner staining to assess erythrocytes and clot formation (bright red) and collagen deposition (green) in Patients' lungs. By assessing three patients from each cluster, we found an increased collagen deposition in Cluster 2 patients, suggesting an increased fibrotic process (Figure 5N). By contrast, samples from Cluster 1 show increased clot formation, suggesting increased thrombotic processes (Figure **50**). Together, these data support the hypothesis that fatal cases of COVID-19

progress via induction of disseminated intravascular coagulation, culminating in a thrombotic process or via a fibrotic process, which is aggravated by the inflammasome-induced exacerbated inflammation.

Discussion

274

275

276

277

278

279

COVID-19 is significantly lethal in nonvaccinated individuals, and although 280 281 inflammation and cytokine storm are associated with poor clinical outcomes, the 282 mechanisms underlying dysregulated inflammatory processes are unknown. The revelation that exacerbated inflammasome activation contributes to COVID-283 19 pathology (Junqueira et al., 2022; Rodrigues et al., 2021; Sefik et al., 2022) 284 advanced the understanding of disease pathology, but a significant proportion 285 286 of the lethal cases progresses with lower inflammasome activation. Our analysis of 47 fatal COVID-19 cases allowed for the classification of the patients into two 287 288 groups. Cluster 2 showed a remarkably high inflammasome activation and hyperexpression of inflammatory genes with increased pulmonary fibrosis and 289 290 worsened respiratory functions. By contrast, patients belonging to Cluster 1 died faster, with higher viral loads, reduced inflammatory process, and increased 291 disseminated intracellular coagulation. Our data reveal two distinct profiles in 292 lethal cases of COVID-19, thus indicating that the balance of viral replication 293 294 and inflammasome-mediated pulmonary inflammation led to different clinical 295 outcomes. 296 Patients belonging to Cluster 2, died of poor respiratory functions and increased 297 fibrosis induced by the excessive inflammatory process. Inflammatory cytokines 298 299 released upon inflammasome activation have been previously linked to the 300 development of pulmonary fibrosis (Cho et al., 2020; Hussain et al., 2014; Lv et 301 al., 2018; Meng et al., 2015; Meng et al., 2019; Sun et al., 2016). In addition, cytokines such as IL-1β, IL-18, and IL-1α have been described as triggering the 302 activation of fibroblasts and stimulating the synthesis and accumulation of type I 303 collagen, TIMP, collagenase, and PGE2 (Hussain et al., 2014; Postlethwaite et 304 al., 1988), which may contribute to the triggering of the deleterious effects of 305 inflammasomes in patients' lungs. Interestingly, patients from Cluster 2 died 306

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

with low viral loads and higher inflammasome activation; in many patients from this cluster, viral loads were not detected, suggesting that SARS-CoV-2 per see may not be required for continuous inflammasome activation in the lungs of these patients. How NLRP3 inflammasome is activated in the tissues is still unknown, it is possible that Damage-Associated Molecular Patterns (DAMPs) participate in this process. Alternatively, it is possible that viral proteins produced before viral elimination or undetectable levels of SARS-CoV-2 present in the tissues are sufficient to activate NLRP3 inflammasome. Future studies will be required to clarify these questions. We also tested whether the mechanical ventilation used in COVID-19 patients would interfere with inflammasome activation. This hypothesis is supported by data indicating that mechanical ventilation-induced hyperoxia can induce potassium efflux through the P₂X₇ receptor, thus leading to inflammasome activation and the secretion of proinflammatory cytokines (Dolinay et al., 2012; Jones et al., 2014; Kolliputi et al., 2010; Kuipers et al., 2012; Wu et al., 2013; Zhang et al., 2014). This does not appear to be the case in our study, as when we separated the COVID-19 patients into two groups according to the use or non-use of mechanical ventilation, we detected no differences in histopathological analyses and inflammasome activation (Table 4). Moreover, we confirmed that patients who underwent mechanical ventilation had a longer illness time, higher hypertension, less CRP and albumin, higher amounts of urea, and worsened pulmonary function (according to the PaO2/FiO2 and A-an O2 gradients). Thus, our data do not support the hypothesis that mechanical ventilation is directly associated with inflammasome activation. The mechanisms underlying dysregulated inflammatory processes and the cell types involved in inflammasome activation in COVID-19 are largely unknown. Macrophages are possibly the most effective cell types that trigger inflammasome activation (Broz and Dixit, 2016); according to this information, our data showed that macrophages in the lungs of COVID-19 patients are effectively infected and strongly induce inflammasome activation. These data are in agreement with previously published articles indicating high levels of viral RNA in lung monocytes and macrophages of COVID-19 patients (Delorey et al.,

340 2021; Pontelli et al., 2022), as well as pronounced inflammasome activation in macrophages from COVID-19 patients (Junqueira et al., 2022; Rodrigues et al., 341 2021; Sefik et al., 2022). In addition to inflammasome activation in 342 macrophages, the analysis of inflammasome activation in different pulmonary 343 cell types indicates that endothelial cells exposed to SARS-CoV-2 express 344 345 inflammasome proteins and contain active NLRP3/ASC puncta, thus demonstrating inflammasome activation. Despite reports indicating that 346 347 endothelial cells are not productively infected by SARS-CoV-2 (Schimmel et al., 2021), precursors of hematopoietic and endothelial cells stimulated with SARS-348 349 CoV-2 spike protein increase the expression of AIM2, NLRP1, NLRP3, IL1B, and ASC and trigger caspase-1 activation (Kucia et al., 2021; Ratajczak et al., 350 351 2021). In addition, inflammasome activation in endothelial cells has been previously reported (Paul et al., 2021; Xiang et al., 2011; Xu et al., 2013; Yang 352 353 et al., 2016). These observations are consistent with our data indicating the 354 expression of inflammasome components and inflammasome activation in CD34+ cells in the lungs of COVID-19 patients. Although these cells were 355 356 stained positive for the SARS-CoV-2 spike protein, it is unknown whether infection and viral replication are required for inflammasome activation in these 357 cells. It is possible that exosomes, released from COVID-19-infected cells, 358 trigger NLRP3 inflammasome in endothelial cells (Sur et al., 2022). 359 Alternatively, It is possible that spike stimulation is sufficient for inflammasome 360 activation, which is a feature that would explain reports indicating damage and 361 dysfunction of these cells during COVID-19 and the characterization of COVID-362 19 as an endothelial disease (Hottz et al., 2020; Libby and Lüscher, 2020; Liu et 363 al., 2021; Nuovo et al., 2021; Varga et al., 2020; Ward et al., 2021). Importantly, 364 vascular endothelium is actively involved in the regulation of inflammation and 365 366 thrombus formation. This is particularly important in COVID-19 because the interplay between inflammasome activation in macrophages and the 367 endothelium can lead to pyroptotic macrophages releasing tissue factor (TF), 368 369 which is an essential initiator of coagulation cascades that are frequently observed in severe cases of COVID-19 (Campos et al., 2021; Wu et al., 2019; 370 Zhang et al., 2021). These data support the association of inflammasomes with 371 372 the coagulopathy that is observed in COVID-19.

In this study, we demonstrated specific cell types involved in inflammasome activation in patients' lungs and identified two distinct profiles in lethal cases of COVID-19. The revealed balance of viral-induced intravascular coagulation versus inflammasome-mediated pulmonary inflammation contributes to our understanding of disease pathophysiology and may contribute to decisions between immune-mediated or antiviral-mediated therapies for the treatment of critical cases of COVID-19.

Methods

373

374

375

376

377

378

379

380

381

382

383

Samples and Study Approval

- Minimally invasive autopsy was performed on 47 patients diagnosed with 384
- SARS-CoV-2 at the Hospital das Clínicas da Faculdade de Medicina de 385
- Ribeirão Preto da Universidade de São Paulo, Brazil (Ribeirão Preto, SP, 386
- Brazil) from April to July, 2020, by Servico de Patologia (SERPAT). Minimally 387
- invasive autopsy was done at bedside through post-mort surgical lung biopsy by 388
- a matching 14-gauge cutting needle (Magnum Needles, Bard) and a biopsy gun 389
- 390 (Magnum, Bard). Moreover, a 3 cm incision on the more affected side of the
- chest between the fourth and fifth ribs were also used to provide extra lung 391
- tissue. All tissue samples were embedded in paraffin and fixed in formalin 392
- (Formalin-Fixed Paraffin- Embedded, FFPE). Lung tissue from biopsy of Lung 393
- Adenocarcinoma patients (n=5) were obtained from SERPAT. The project was 394
- approved by the Research Ethics Committee of FMRP/USP under protocol no 395
- 4,089.567. 396

397

398

Immunohistochemistry (IHC)

- 399 Tissue section in paraffin blocks were tested by immunohistochemistry using
- antibodies for the detection of NLRP3 (clone D2P5E; 1:3,000; Cell Signaling), 400
- ASC (1:2,000; Adipogen AL177), SFTPC (1:200, ThermoFisher PA5-71680). 401
- CD68 (1:200, Dako M0814), CD34 (1:500, Zeta Z2063ML), PDPN (1:200, 402
- ThermoFisher 14-9381-82), Anti-cleaved N-terminal GSDMD (1:200, Abcam 403

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

ab215203), Caspase-1 (1:200, Abcam ab207802), IL-1β (1:200, Abcam 404 ab2105) for the in situ detection of these inflammasome proteins. The 405 Sequential Immunoperoxidase Labeling and Erasing (SIMPLE) technique was 406 used to evaluate all markers in the same tissue, as previously published (Glass 407 et al., 2009). Briefly, after incubation with primary antibody (overnight at 4°C). 408 409 slides were incubated with immune peroxidase polymer anti-mouse visualization system (SPD-125, Spring Bioscience, 345 Biogen) and with 410 chromogen-substrate AEC peroxidase system kit (SK-4200, 346 Vector 411 Laboratories, Burlingame, CA). After high resolution scanning by a VS120 412 413 Olympus microscope, the coverslips were removed in PBS and the slides were dehydrated in an ethanol gradient to 95% ethanol. The slides were incubated in 414 415 a series of ethanol to erase the AEC marking. Afterwards the slides were rehydrated and the antibodies were removed with an incubation for 2 min in a 416 417 solution of 0.15 mM 351 KMnO4/0.01 M H₂SO₄, followed immediately by a wash in distilled water. Tissues were then remarked. 418 419 420 *Immunofluorescence* 421 The slides were incubated with the primary antibodies, rabbit anti-human NLRP3 mAb (clone D2P5E; 1:300; Cell Signaling), rabbit anti-human ASC 422 423 polyclonal antibody (1:200; Adipogen AL177), SFTPC (1:200, ThermoFisher 424 PA5-71680), CD64 (1:200, Biolegend 139304), CD34 (1:500, Zeta Z2063ML), PDPN (1:200, ThermoFisher 14-9381-82), overnight at 4°C and with the 425 426 secondary antibodies Goat anti-mouse Alexa fluor-647 (Invitrogen) or Goat antirabbit Alexa fluor-594 (Invitrogen). Images were acquired by the Axio Observer 427 428 system combined with the LSM 780 confocal device microscope at 63x magnification (Carl Zeiss). 429 430 Histological Evaluation 431 Paraffin-embedded lung tissues sections (3 µm) were stained by standard 432 hematoxylin and eosin (H&E). Morphological lung injury patterns were 433 434 evaluated by specialized pulmonary pathologists (ATF) blinded to clinical history. They were classified as absent or present with its extent of lung injury 435 area by 5% cut-offs in Fibrosis, Organizing Pneumonia (OP), Acute Fibrinous 436

and Organizing Pneumonia (AFOP), Diffuse Alveolar Damage (DAD), Cellular Pneumonitis, Thrombus Formation.

437

438

467

439 RNA extraction and Real-Time Polymerase Chain Reaction for 440 inflammatory genes 441 Total RNA from fresh lung tissue of SARS-CoV-2 patients and controls was 442 obtained using Trizol reagent, and purification was performed according to the 443 444 manufacturer's instructions. The RNA was quantified by spectrophotometry in a NanoDrop 2000c spectrophotometer. The concentration was adjusted to 1 445 µg/µL, and the RNA was stored at −70 °C until reverse transcription. For 446 447 inflammatory genes qPCR the total RNA was transcribed into complementary DNA (cDNA) using a High-Capacity cDNA Reverse Transcription kit (without an 448 449 inhibitor) according to the protocol provided by the manufacturer (Thermo Fisher, Carlsbad, CA, USA). The reaction was prepared in a final volume of 450 451 20.0 µL containing 4.2 µL of H₂O, 2.0 µL of buffer, 2.0 µL of random primers, 0.8 µL of dNTP Mix (100 mM), 1.0 µL of reverse transcriptase (RT) enzyme and 452 453 1 μL of RNA (1 ug/μL). The solution was then placed into a thermocycler with the following program: 25 °C for 10 min, 37 °C for 120 min and 85 °C for 5 min. 454 The real-time PCR was performed in 96-well plates using Sybr Green reagents 455 (Applied Biosystems, Waltham, MA, USA) and a Quant studio real-time PCR 456 457 system (Applied Biosystems, Foster City, CA, USA). The real time-RT-PCR was carried out in a total volume of 20 µl on a 96-well MicroAmp Fast Optical plate 458 (Applied Biosystems). Each well contained 10 µl SYBR Green gPCR Master 459 Mix (Thermofisher), 1 µl of each primer (Supplementary Table 1), 2 µl cDNA 460 (20 ng) and 7 µl RNase free water using the following protocol: initial 461 denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 s 462 463 followed by annealing/extension at 60°C for 60 s. Each PCR was followed by a 464 dissociation curve analysis between 60-95°C. The Ct values were analyzed by the comparative Ct ($\Delta\Delta$ Ct) method and normalized to the endogenous control 465 GAPDH. Fold difference was calculated as 2^{-ΔΔCt} 466

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Real-Time Polymerase Chain Reaction for Viral RNA

- Detection and quantification of SARS-CoV-2 genes was performed with primer-
- 470 probe sets for 2019-nCoV_N2 and gene E, according to US Centers for
- Disease Control and Prevention (Lu et al., 2020) and Charité group protocols
- (Corman et al., 2020). The genes evaluated (N2, E, and RNase-P
- 473 housekeeping gene) were tested by one-step real-time RT-PCR using total
- 474 nucleic acids extracted with TRIzol (Invitrogen). All real-time PCR assays were
- done on a Quant studio real-time PCR system (Applied Biosystems, Foster City,
- 476 CA, USA). A total of 70 ng of RNA was used for genome amplification, adding
- specific primers (20 μM), and probe (5 μM), and with TaqPath 1-Step
- 478 quantitative RT-PCR Master Mix (Applied Biosystems), with the following
- parameters: 25°C for 2 min, 50°C for 15 min, and 95°C for 2 min, followed by 45
- cycles of 94°C for 5 s and 60°C for 30 s. Primers used were the following: N2
- 481 forward: 5'-TTACAAACATTGGCCGCAAA-3', N2 reverse: 5'-
- 482 GCGCGACATTCCGAAGAA-3'; N2 probe: 5'-FAM-
- 483 ACAATTTGCCCCCAGCGCTTCAG-BHQ1-3' (Lu et al., 2020); E forward: 5'-
- 484 ACAGGTACGTTAATAGTTAATAGCGT-3', E reverse: 5'-
- 485 ATATTGCAGCAGTACGCACACA-3'; E probe: 5'-AM-
- 486 ACACTAGCCATCCTTACTGCGCTTCG-BHQ-1-3' (Corman et al., 2020);
- 487 RNase-P forward: 5'-AGATTTGGACCTGCGAGCG-3', RNase-P reverse: 5'-
- 488 GAGCGGCTGTCTCCACAAGT-3'; and RNase-P probe: 5'-FAM-
- 489 TTCTGACCTGAAGGCTCTGCGCG-BHQ-1-3' (Lu et al., 2020). A plasmid of
- N2 protein and E protein was used for a standard curve construction for viral
- 491 load quantification.

492

468

Chest computed tomography images acquisition and evaluation

- Chest x-radiography (CXR) and computed tomography (CT) exams were
- 494 performed as part of the routine clinical evaluation. Chest radiographies were
- 495 performed in conventional equipment, mainly in the anteroposterior incidence.
- 496 CT images were performed in multidetector scanners (Brilliance CT Big Bore 16
- Philips, Holland, or Aquilion Prime 160 Toshiba, Japan), using similar
- 498 protocols for the acquisition of high-resolution images of the lungs (Raghu et al.,
- 499 2018). Patients were scanned in the supine position without the administration
- of intravenous contrast media. Typical acquisition parameters were: 120 kVp

tube voltage, 100–140 ref mAs (Koenigkam-Santos et al., 2022), 0.3–0.7 s gantry rotation time, reconstruction matrix size of 512×512, slice thickness, and increment of 1.0 mm, using standard (soft) and hard kernel filters. Imaging exams were independently evaluated by two thoracic radiologists (MKS and DTW), blinded to clinical data, laboratory, and pathology results as described (Koenigkam-Santos et al., 2022). Divergences were solved by consensus. All CXRs available were classified for the presence and grade of viral pneumonia (Revel et al., 2020). Pulmonary disease evolution on imaging was evaluated considering all exams from the initial to the last image before death. Tomographic images were evaluated similarly to CXR images.

Statistical Analysis

501

502

503

504

505

506

507

508 509

510

511

512

For puncta quantification, all histological sections were viewed on a 63x 513 514 objective for digitalizing random images using the LSM 780 system in the Axio Observer microscope, covering an area of about ~1.7 mm² of lung parenchyma 515 analyzed per case. Manual counting of puncta and cells was blinded and 516 517 performed using the acquired images. Morphometric analyzes were performed as described (Weibel, 1963). The quantification of expression by 518 519 immunohistochemistry was performed by calculating the percentage of marked area, the scanned images were opened in the ImageJ software, using the IHQ 520 521 Toolbox plugin, which consists of a semi-automatic color selection tool that 522 selects the pixels positive for immunohistochemical marking, differentiating 523 them from background and H&E marking, after selecting the positive pixels, the images were transformed into 8-bits and the area occupied by these tones was 524 calculated. The distribution of the gene expression and biochemical marker and 525 puncta count data was evaluated using the Shapiro-Wilk test; the data were 526 analyzed using non-parametric Kruskal-Wallis, Mann-Whitney test and 527 528 Spearman correlation. The data as violin plot graphs show median and quartiles. Statistical analyzes were performed using the GraphPad PRISM 5.0 529 program, with p<0.05 being considered statistically significant. Heatmaps were 530 constructed using the heatmap.2 function in the R program (Project for 531 Statistical Computing, version 3.4.1), the hierarchical clustering method used a 532 533 correlation distance measure with ward.D2 and Canberra analysis.

Acknowledgments: We would like to thank Maira Nakamura, Amanda Zuin and Dr. Roberta Sales for technical support.

Funding: Fundação de Amparo à Pesquisa do Estado de Sao Paulo, FAPESP grants 2013/08216-2, 2019/11342-6 and 2020/04964-8. Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq grant 303021/2020-9. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES grant 88887.507253/2020-00.

Competing interests: Authors declare that they have no competing interests.

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

References

546

547

550

551

581

582

- Batah, S.S., and A.T. Fabro. 2021. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. *Respir Med* 176:106239.
 - Bösmüller, H., M. Matter, F. Fend, and A. Tzankov. 2021. The pulmonary pathology of COVID-19. *Virchows Arch* 478:137–150.
- Broz, P., and V.M. Dixit. 2016. Inflammasomes: mechanism of assembly, regulation and signalling. *Nat Rev Immunol* 16:407-420.
- 554 Cama, V.F., J. Marín-Prida, N. Acosta-Rivero, E.F. Acosta, L.O. Díaz, A.V. Casadesús, B. Fernández-Marrero, N. Gilva-Rodríguez, D. Cremata-555 García, M. Cervantes-Llanos, B. Piniella-Matamoros, D. Sánchez, L. Del 556 Rosario-Cruz, I. Borrajero, A. Díaz, Y. González, E. Pentón-Arias, T. 557 Montero-González, G. Guillen-Nieto, and G. Pentón-Rol, 2021. The 558 559 microglial NLRP3 inflammasome is involved in human SARS-CoV-2 cerebral pathogenicity: A report of three post-mortem cases. J 560 Neuroimmunol 361:577728. 561
- Campos, J., T. Ponomaryov, A. De Prendergast, K. Whitworth, C.W. Smith,
 A.O. Khan, D. Kavanagh, and A. Brill. 2021. Neutrophil extracellular traps
 and inflammasomes cooperatively promote venous thrombosis in mice.
 Blood Adv 5:2319-2324.
- Chen, H., W. Liu, Y. Wang, D. Liu, L. Zhao, and J. Yu. 2021. SARS-CoV-2
 activates lung epithelial cell proinflammatory signaling and leads to immune
 dysregulation in COVID-19 patients. *EBioMedicine* 70:103500.
- Cho, S.J., J.S. Moon, K. Nikahira, H.S. Yun, R. Harris, K.S. Hong, H. Huang,
 A.M.K. Choi, and H. Stout-Delgado. 2020. GLUT1-dependent glycolysis
 regulates exacerbation of fibrosis via AIM2 inflammasome activation.
 Thorax 75:227-236.
- Corman, V.M., O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, T. 573 Bleicker, S. Brünink, J. Schneider, M.L. Schmidt, D.G. Mulders, B.L. 574 Haagmans, B. van der Veer, S. van den Brink, L. Wijsman, G. Goderski, 575 J.L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken, 576 M.P. Koopmans, and C. Drosten. 2020. Detection of 2019 novel 577 coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance: bulletin 578 Europeen sur les maladies transmissibles = European communicable 579 disease bulletin 25: 580
 - Cui, H., and L. Zhang. 2020. Key Components of Inflammasome and Pyroptosis Pathways Are Deficient in Canines and Felines, Possibly Affecting Their Response to SARS-CoV-2 Infection. *Front Immunol* 11:592622.
- Delorey, T.M., C.G.K. Ziegler, G. Heimberg, R. Normand, Y. Yang, Å.
 Segerstolpe, D. Abbondanza, S.J. Fleming, A. Subramanian, D.T. Montoro,
 K.A. Jagadeesh, K.K. Dey, P. Sen, M. Slyper, Y.H. Pita-Juárez, D. Phillips,
 J. Biermann, Z. Bloom-Ackermann, N. Barkas, A. Ganna, J. Gomez, J.C.
 Melms, I. Katsyv, E. Normandin, P. Naderi, Y.V. Popov, S.S. Raju, S.
- Niezen, L.T. Tsai, K.J. Siddle, M. Sud, V.M. Tran, S.K. Vellarikkal, Y. Wang, L. Amir-Zilberstein, D.S. Atri, J. Beechem, O.R. Brook, J. Chen, P. Divakar,
- P. Dorceus, J.M. Engreitz, A. Essene, D.M. Fitzgerald, R. Fropf, S. Gazal,
- J. Gould, J. Grzyb, T. Harvey, J. Hecht, T. Hether, J. Jané-Valbuena, M.
- Leney-Greene, H. Ma, C. McCabe, D.E. McLoughlin, E.M. Miller, C. Muus,

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

- M. Niemi, R. Padera, L. Pan, D. Pant, C. Pe'er, J. Pfiffner-Borges, C.J.
- Pinto, J. Plaisted, J. Reeves, M. Ross, M. Rudy, E.H. Rueckert, M.
- 596 Siciliano, A. Sturm, E. Todres, A. Waghray, S. Warren, S. Zhang, D.R.
- Zollinger, L. Cosimi, R.M. Gupta, N. Hacohen, H. Hibshoosh, W. Hide, A.L.
- 598 Price, J. Rajagopal, P.R. Tata, S. Riedel, G. Szabo, T.L. Tickle, P.T. Ellinor,
- D. Hung, P.C. Sabeti, R. Novak, R. Rogers, D.E. Ingber, Z.G. Jiang, D.
- Juric, M. Babadi, S.L. Farhi, B. Izar, J.R. Stone, I.S. Vlachos, I.H. Solomon,
- O. Ashenberg, C.B.M. Porter, B. Li, A.K. Shalek, A.C. Villani, O. Rozenblatt-
- Rosen, and A. Regev. 2021. COVID-19 tissue atlases reveal SARS-CoV-2
- pathology and cellular targets. *Nature* 595:107-113.
- Dolinay, T., Y.S. Kim, J. Howrylak, G.M. Hunninghake, C.H. An, L.
- Fredenburgh, A.F. Massaro, A. Rogers, L. Gazourian, K. Nakahira, J.A. Haspel, R. Landazury, S. Eppanapally, J.D. Christie, N.J. Meyer, L.B. Ware,
- D.C. Christiani, S.W. Ryter, R.M. Baron, and A.M. Choi. 2012.
- Inflammasome-regulated cytokines are critical mediators of acute lung
- injury. *American journal of respiratory and critical care medicine* 185:1225-1234.
- Eisfeld, H.S., A. Simonis, S. Winter, J. Chhen, L.J. Ströh, T. Krey, M. Koch, S.J. Theobald, and J. Rybniker. 2021. Viral Glycoproteins Induce NLRP3
 Inflammasome Activation and Pyroptosis in Macrophages. *Viruses* 13:
- 614 Glass, G., J.A. Papin, and J.W. Mandell. 2009. SIMPLE: a sequential 615 immunoperoxidase labeling and erasing method. *J Histochem Cytochem* 616 57:899-905.
- Hariri, L.P., C.M. North, A.R. Shih, R.A. Israel, J.H. Maley, J.A. Villalba, V.
- Vinarsky, J. Rubin, D.A. Okin, A. Sclafani, J.W. Alladina, J.W. Griffith, M.A.
- Gillette, Y. Raz, C.J. Richards, A.K. Wong, A. Ly, Y.P. Hung, R.R.
- 620 Chivukula, C.R. Petri, T.F. Calhoun, L.N. Brenner, K.A. Hibbert, B.D.
- Medoff, C.C. Hardin, J.R. Stone, and M. Mino-Kenudson. 2021. Lung
- Histopathology in Coronavirus Disease 2019 as Compared With Severe
- Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review.
- 624 Chest 159:73-84.

632

Blood 136:1330-1341.

- Hauenstein, A.V., L. Zhang, and H. Wu. 2015. The hierarchical structural architecture of inflammasomes, supramolecular inflammatory machines. *Current opinion in structural biology* 31:75-83.
- Hottz, E.D., I.G. Azevedo-Quintanilha, L. Palhinha, L. Teixeira, E.A. Barreto, C.R.R. Pao, C. Righy, S. Franco, T.M.L. Souza, P. Kurtz, F.A. Bozza, and P.T. Bozza. 2020. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19.
- Huang, K.J., I.J. Su, M. Theron, Y.C. Wu, S.K. Lai, C.C. Liu, and H.Y. Lei. 2005.
 An interferon-gamma-related cytokine storm in SARS patients. *J Med Virol*75:185-194.
- Hussain, S., S. Sangtian, S.M. Anderson, R.J. Snyder, J.D. Marshburn, A.B. Rice, J.C. Bonner, and S. Garantziotis. 2014. Inflammasome activation in airway epithelial cells after multi-walled carbon nanotube exposure mediates a profibrotic response in lung fibroblasts. *Part Fibre Toxicol* 11:28.
- Jones, H.D., T.R. Crother, R.A. Gonzalez-Villalobos, M. Jupelli, S. Chen, J.
- Dagvadorj, M. Arditi, and K. Shimada. 2014. The NLRP3 inflammasome is
- required for the development of hypoxemia in LPS/mechanical ventilation
- acute lung injury. *Am J Respir Cell Mol Biol* 50:270-280.

- Junqueira, C., Â. Crespo, S. Ranjbar, L.B. de Lacerda, M. Lewandrowski, J. 644 645 Ingber, B. Parry, S. Ravid, S. Clark, M.R. Schrimpf, F. Ho, C. Beakes, J. Margolin, N. Russell, K. Kays, J. Boucau, U. Das Adhikari, S.M. Vora, V. 646 Leger, L. Gehrke, L. Henderson, E. Janssen, D. Kwon, C. Sander, J. 647 Abraham, M.B. Goldberg, H. Wu, G. Mehta, S. Bell, A.E. Goldfeld, M.R. 648 Filbin, and J. Lieberman. 2022. FcyR-mediated SARS-CoV-2 infection of 649
- monocytes activates inflammation. Nature 650 651 Koenigkam-Santos, M., D.T. Wada, M.N. Benatti, L. Siyuan, S.S. Batah, A.A. Cetlin, M.B. de Menezes, and A.T. Fabro. 2022. SARS-Cov-2 pneumonia 652

phenotyping on imaging exams of patients submitted to minimally invasive 653 654 autopsy. Ann Transl Med 10:140.

- Kolliputi, N., R.S. Shaik, and A.B. Waxman. 2010. The inflammasome mediates 655 hyperoxia-induced alveolar cell permeability. J Immunol 184:5819-5826. 656
- 657 Kommoss, F.K.F., C. Schwab, L. Tavernar, J. Schreck, W.L. Wagner, U. Merle, D. Jonigk, P. Schirmacher, and T. Longerich. 2020. The Pathology of 658 659 Severe COVID-19-Related Lung Damage. Dtsch Arztebl Int 117:500-506.
- Kucia, M., J. Ratajczak, K. Bujko, M. Adamiak, A. Ciechanowicz, V. Chumak, K. 660 661 Brzezniakiewicz-Janus, and M.Z. Ratajczak. 2021. An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic 662 stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 663 664 inflammasome-dependent manner. Leukemia 1-4.
- Kuipers, M.T., H. Aslami, J.R. Janczy, K.F. van der Sluijs, A.P. Vlaar, E.K. 665 Wolthuis, G. Choi, J.J. Roelofs, R.A. Flavell, F.S. Sutterwala, P. Bresser, 666 667 J.C. Leemans, T. van der Poll, M.J. Schultz, and C.W. Wieland. 2012. Ventilator-induced lung injury is mediated by the NLRP3 inflammasome. 668 Anesthesiology 116:1104-1115. 669
- 670 Libby, P., and T. Lüscher. 2020. COVID-19 is, in the end, an endothelial disease. Eur Heart J 41:3038-3044. 671
- Liu, J., Y. Li, Q. Liu, Q. Yao, X. Wang, H. Zhang, R. Chen, L. Ren, J. Min, F. 672 Deng, B. Yan, L. Liu, Z. Hu, M. Wang, and Y. Zhou, 2021, SARS-CoV-2 cell 673 tropism and multiorgan infection. In Cell Discov. 17. 674
- Lu, X., L. Wang, S.K. Sakthivel, B. Whitaker, J. Murray, S. Kamili, B. Lynch, L. 675 Malapati, S.A. Burke, J. Harcourt, A. Tamin, N.J. Thornburg, J.M. 676 Villanueva, and S. Lindstrom. 2020. US CDC Real-Time Reverse 677 Transcription PCR Panel for Detection of Severe Acute Respiratory 678 Syndrome Coronavirus 2. Emerg Infect Dis 26:1654-1665. 679
- Lucas, C.W., P. LKlein, J. et al. 2020. Longitudinal analyses reveal 680 immunological misfiring in severe COVID-19. Nature 681
- Lv, Z., Y. Wang, Y.J. Liu, Y.F. Mao, W.W. Dong, Z.N. Ding, G.X. Meng, L. 682 Jiang, and X.Y. Zhu. 2018. NLRP3 Inflammasome Activation Contributes to 683 684 Mechanical Stretch-Induced Endothelial-Mesenchymal Transition and Pulmonary Fibrosis. Crit Care Med 46:e49-e58. 685
- Meng, Y., T. Li, G.S. Zhou, Y. Chen, C.H. Yu, M.X. Pang, W. Li, Y. Li, W.Y. 686 Zhang, and X. Li. 2015. The angiotensin-converting enzyme 2/angiotensin 687 (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by 688 689 inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway. Antioxid Redox Signal 22:241-258. 690
- Meng, Y., M. Pan, B. Zheng, Y. Chen, W. Li, Q. Yang, Z. Zheng, N. Sun, Y. 691 692 Zhang, and X. Li. 2019. Autophagy Attenuates Angiotensin II-Induced 693 Pulmonary Fibrosis by Inhibiting Redox Imbalance-Mediated NOD-Like

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

```
Receptor Family Pyrin Domain Containing 3 Inflammasome Activation.
694
695
          Antioxid Redox Signal 30:520-541.
```

- Nuovo, G.J., C. Magro, T. Shaffer, H. Awad, D. Suster, S. Mikhail, B. He, J.J. 696 Michaille, B. Liechty, and E. Tili. 2021. Endothelial cell damage is the 697 central part of COVID-19 and a mouse model induced by injection of the S1 698 subunit of the spike protein. Annals of diagnostic pathology 51:151682. 699
- Olajide, O.A., V.U. Iwuanyanwu, I. Lepiarz-Raba, and A.A. Al-Hindawi. 2021. 700 701 Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 702 and Its Inhibition by Dexamethasone. Inflammation 44:1865-1877. 703
- 704 Paul, O., J.Q. Tao, L. Litzky, M. Feldman, K. Montone, C. Rajapakse, C. 705 Bermudez, and S. Chatterjee. 2021. Vascular Inflammation in Lungs of 706 Patients with Fatal Coronavirus Disease 2019 (COVID-19) Infection: Possible role for the NLRP3 inflammasome. *medRxiv* 707
- Polak, S.B., I.C. Van Gool, D. Cohen, J.H. von der Thüsen, and J. van Paassen. 708 2020. A systematic review of pathological findings in COVID-19: a 709 pathophysiological timeline and possible mechanisms of disease 710 711 progression. Mod Pathol 33:2128-2138.
- Pontelli, M.C., I.A. Castro, R.B. Martins, L. La Serra, F.P. Veras, D.C. 712 Nascimento, C.M. Silva, R.S. Cardoso, R. Rosales, R. Gomes, T.M. Lima, 713 714 J.P. Souza, B.C. Vitti, D.B. Caetite, M.H.F. de Lima, S.D. Stumpf, C.E. 715 Thompson, L.M. Bloyet, J.T.E. Kawahisa, M.C. Giannini, L.P. Bonjorno, M.I.F. Lopes, S.S. Batah, S. Li, R.L. Assad, S.C.L. Almeida, F.R. Oliveira, 716 717 M.N. Benatti, L.L.F. Pontes, R.C. Santana, F.C. Vilar, M.A. Martins, P.Y. 718 Shi, T.M. Cunha, R.T. Calado, J.C. Alves-Filho, D.S. Zamboni, A. Fabro, P. Louzada-Junior, R.D.R. Oliveira, S.P.J. Whelan, F.Q. Cunha, and E. 719 720 Arruda. 2022. SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients. J Mol Cell Biol 721
- Postlethwaite, A.E., R. Raghow, G.P. Stricklin, H. Poppleton, J.M. Seyer, and 722 A.H. Kang, 1988. Modulation of fibroblast functions by interleukin 1: 723 increased steady-state accumulation of type I procollagen messenger RNAs 724 725 and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol 106:311-318. 726
- Qin, C., L. Zhou, Z. Hu, S. Zhang, S. Yang, Y. Tao, C. Xie, K. Ma, K. Shang, W. 727 Wang, and D.S. Tian. 2020. Dysregulation of Immune Response in Patients 728 With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 729 730 71:762-768.
- Raghu, G., M. Remy-Jardin, J.L. Myers, L. Richeldi, C.J. Ryerson, D.J. Lederer, 731 J. Behr, V. Cottin, S.K. Danoff, F. Morell, K.R. Flaherty, A. Wells, F.J. 732 Martinez, A. Azuma, T.J. Bice, D. Bouros, K.K. Brown, H.R. Collard, A. 733 734 Duggal, L. Galvin, Y. Inoue, R.G. Jenkins, T. Johkoh, E.A. Kazerooni, M. Kitaichi, S.L. Knight, G. Mansour, A.G. Nicholson, S.N.J. Pipavath, I. 735 Buendia-Roldan, M. Selman, W.D. Travis, S. Walsh, K.C. Wilson, 736 E.R.S.J.R.S. American Thoracic Society, and S. Latin American Thoracic. 737
- 738 2018. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official
- ATS/ERS/JRS/ALAT Clinical Practice Guideline. American journal of 739 respiratory and critical care medicine 198:e44-e68. 740
- 741 Ratajczak, M.Z., K. Bujko, A. Ciechanowicz, K. Sielatycka, M. Cymer, W. 742 Marlicz, and M. Kucia. 2021. SARS-CoV-2 Entry Receptor ACE2 Is
- Expressed on Very Small CD45(-) Precursors of Hematopoietic and 743

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

- Endothelial Cells and in Response to Virus Spike Protein Activates the 744 745 Nlrp3 Inflammasome. Stem Cell Rev Rep 17:266-277.
- Revel, M.P., A.P. Parkar, H. Prosch, M. Silva, N. Sverzellati, F. Gleeson, A. 746 Brady, R. European Society of, and I. the European Society of Thoracic. 747 2020. COVID-19 patients and the radiology department - advice from the 748 European Society of Radiology (ESR) and the European Society of 749 Thoracic Imaging (ESTI). Eur Radiol 30:4903-4909. 750
- 751 Rodrigues, T.S., K.S.G. de Sá, A.Y. Ishimoto, A. Becerra, S. Oliveira, L. Almeida, A.V. Gonçalves, D.B. Perucello, W.A. Andrade, R. Castro, F.P. 752 Veras, J.E. Toller-Kawahisa, D.C. Nascimento, M.H.F. de Lima, C.M.S. 753 754 Silva, D.B. Caetite, R.B. Martins, I.A. Castro, M.C. Pontelli, F.C. de Barros, 755 N.B. do Amaral, M.C. Giannini, L.P. Bonjorno, M.I.F. Lopes, R.C. Santana, F.C. Vilar, M. Auxiliadora-Martins, R. Luppino-Assad, S.C.L. de Almeida, 756 F.R. de Oliveira, S.S. Batah, L. Siyuan, M.N. Benatti, T.M. Cunha, J.C. 757 Alves-Filho, F.Q. Cunha, L.D. Cunha, F.G. Frantz, T. Kohlsdorf, A.T. Fabro, 758 E. Arruda, R.D.R. de Oliveira, P. Louzada-Junior, and D.S. Zamboni. 2021. 759 Inflammasomes are activated in response to SARS-CoV-2 infection and are 760 associated with COVID-19 severity in patients. J Exp Med 218: 761
- Sauter, J.L., M.K. Baine, K.J. Butnor, D.J. Buonocore, J.C. Chang, A.A. 762 Jungbluth, M.J. Szabolcs, S. Morjaria, S.L. Mount, N. Rekhtman, E. Selbs, 763 Z.M. Sheng, Y. Xiao, D.E. Kleiner, S. Pittaluga, J.K. Taubenberger, A.V. 764 Rapkiewicz, and W.D. Travis. 2020. Insights into pathogenesis of fatal 765 COVID-19 pneumonia from histopathology with immunohistochemical and 766 767 viral RNA studies. Histopathology 77:915-925.
- Schimmel, L., K.Y. Chew, C.J. Stocks, T.E. Yordanov, P. Essebier, A. 768 Kulasinghe, J. Monkman, A.F.R. Dos Santos Miggiolaro, C. Cooper, L. de 769 770 Noronha, K. Schroder, A.K. Lagendijk, L.I. Labzin, K.R. Short, and E.J. Gordon. 2021. Endothelial cells are not productively infected by SARS-CoV-771 2. Clin Transl Immunology 10:e1350. 772
- Sefik, E., R. Qu, C. Junqueira, E. Kaffe, H. Mirza, J. Zhao, J.R. Brewer, A. Han, 773 H.R. Steach, B. Israelow, H.N. Blackburn, S. Velazguez, Y.G. Chen, S. 774 Halene, A. Iwasaki, E. Meffre, M. Nussenzweig, J. Lieberman, C.B. Wilen, 775 Y. Kluger, and R.A. Flavell. 2022. Inflammasome activation in infected 776 macrophages drives COVID-19 pathology. Nature 777
- Sinha, P., M.A. Matthay, and C.S. Calfee. 2020. Is a "Cytokine Storm" Relevant 778 to COVID-19? In JAMA Intern Med. United States. 1152-1154. 779
- Sun, B., X. Wang, Y.P. Liao, Z. Ji, C.H. Chang, S. Pokhrel, J. Ku, X. Liu, M. 780 Wang, D.R. Dunphy, R. Li, H. Meng, L. Mädler, C.J. Brinker, A.E. Nel, and 781 T. Xia. 2016. Repetitive Dosing of Fumed Silica Leads to Profibrogenic 782 Effects through Unique Structure-Activity Relationships and Biopersistence 783 784 in the Lung. ACS Nano 10:8054-8066.
- Sur, S., R. Steele, T.S. Isbell, R. Ray, and R.B. Ray, 2022. Circulatory 785 Exosomes from COVID-19 Patients Trigger NLRP3 Inflammasome in 786 Endothelial Cells. mBio 13:e0095122. 787
- 788 Taylor, F.B., Jr., C.H. Toh, W.K. Hoots, H. Wada, M. Levi, T. Scientific Subcommittee on Disseminated Intravascular Coagulation of the 789 International Society on, and Haemostasis. 2001. Towards definition, 790 clinical and laboratory criteria, and a scoring system for disseminated 791 792

intravascular coagulation. Thromb Haemost 86:1327-1330.

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

- Toldo, S., R. Bussani, V. Nuzzi, A. Bonaventura, A.G. Mauro, A. Cannatà, R.
 Pillappa, G. Sinagra, P. Nana-Sinkam, P. Sime, and A. Abbate. 2021.
 Inflammasome formation in the lungs of patients with fatal COVID-19.
 Inflamm Res 70:7-10.
- Varga, Z., A.J. Flammer, P. Steiger, M. Haberecker, R. Andermatt, A.S.
 Zinkernagel, M.R. Mehra, R.A. Schuepbach, F. Ruschitzka, and H. Moch.
 2020. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 395:1417-1418.
- Ward, S.E., G.F. Curley, M. Lavin, H. Fogarty, E. Karampini, N.L. McEvoy, J. Clarke, M. Boylan, R. Alalqam, A.P. Worrall, C. Kelly, E. de Barra, S. Glavey, C. Ni Cheallaigh, C. Bergin, I. Martin-Loeches, L. Townsend, P.W. Mallon, J.M. O'Sullivan, and J.S. O'Donnell. 2021. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. *Br J Haematol* 192:714-719.
 - Weibel, E.R. 1963. Principles and methods for the morphometric study of the lung and other organs. *Lab Invest* 12:131-155.
- WHO. 2020. World Health Organization, https://covid19.who.int/.

807

808

- Wu, C., W. Lu, Y. Zhang, G. Zhang, X. Shi, Y. Hisada, S.P. Grover, X. Zhang, L.
 Li, B. Xiang, J. Shi, X.A. Li, A. Daugherty, S.S. Smyth, D. Kirchhofer, T.
 Shiroishi, F. Shao, N. Mackman, Y. Wei, and Z. Li. 2019. Inflammasome
 Activation Triggers Blood Clotting and Host Death through Pyroptosis. *Immunity* 50:1401-1411.e1404.
- Wu, J., Z. Yan, D.E. Schwartz, J. Yu, A.B. Malik, and G. Hu. 2013. Activation of NLRP3 inflammasome in alveolar macrophages contributes to mechanical stretch-induced lung inflammation and injury. *J Immunol* 190:3590-3599.
- Xiang, M., X. Shi, Y. Li, J. Xu, L. Yin, G. Xiao, M.J. Scott, T.R. Billiar, M.A. Wilson, and J. Fan. 2011. Hemorrhagic shock activation of NLRP3 inflammasome in lung endothelial cells. *J Immunol* 187:4809-4817.
- Xu, P., Z. Wen, X. Shi, Y. Li, L. Fan, M. Xiang, A. Li, M.J. Scott, G. Xiao, S. Li, T.R. Billiar, M.A. Wilson, and J. Fan. 2013. Hemorrhagic shock augments NIrp3 inflammasome activation in the lung through impaired pyrin induction. *J Immunol* 190:5247-5255.
- Xu, Z., L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, S. Liu, P. Zhao, H. Liu,
 L. Zhu, Y. Tai, C. Bai, T. Gao, J. Song, P. Xia, J. Dong, J. Zhao, and F.S.
 Wang. 2020. Pathological findings of COVID-19 associated with acute
 respiratory distress syndrome. *Lancet Respir Med* 8:420-422.
- Yang, J., Y. Zhao, P. Zhang, Y. Li, Y. Yang, J. Zhu, X. Song, G. Jiang, and J. Fan. 2016. Hemorrhagic shock primes for lung vascular endothelial cell pyroptosis: role in pulmonary inflammation following LPS. *Cell Death Dis* 7:e2363.
- Zhang, Y., J. Cui, G. Zhang, C. Wu, A. Abdel-Latif, S.S. Smyth, T. Shiroishi, N. Mackman, Y. Wei, M. Tao, and Z. Li. 2021. Inflammasome activation promotes venous thrombosis through pyroptosis. *Blood Adv* 5:2619-2623.
- Zhang, Y., G. Liu, R.O. Dull, D.E. Schwartz, and G. Hu. 2014. Autophagy in pulmonary macrophages mediates lung inflammatory injury via NLRP3 inflammasome activation during mechanical ventilation. *Am J Physiol Lung Cell Mol Physiol* 307:L173-185.

Table 1 COVID-19 natient characteristics

Table 1. COVID-19 patient characteristics		
Demographic Characteristics	Mean (±SD) or	
	N (%)	
N	47	
Sex		
Female	23 (48.93%)	
Age (years)	67.97 (15.05±)	
Illness Time (days)	$18.08 (11.04\pm)$	
ICU	37 (78.72%)	
Comorbidities		
Hypertension	26 (55.32%)	
BMI	$31.10 (\pm 8.82)$	
Diabetes	18 (38.29%)	
History of smoking	12 (25.53%)	
Heart disease	12 (25.53%)	
Lung disease	12 (25.53%)	
Kidney disease	7 (14.89%)	
History of stroke	7 (14.89%)	
Autoimmune diseases	2 (4.25%)	
Laboratorial findings	,	
CRP (mg/dL)	11.40 (±8.49)	
D-Dimers (µg/mL)	$4.91 (\pm 4.46)$	
LDH (mmol/L)	$5.01 (\pm 5.24)$	
Creatinine (mg/dL)	$2.22(\pm 1.4)$	
Urea (mg/dL)	119.40 (±58.47)	
AST (IU/L)	104.42 (±90.74)	
ALT (IU/L)	$72.12 (\pm 55.14)$	
AST/ALT	$1.8 (\pm 1.60)$	
PT (INR)	$1.81 (\pm 2.13)$	
Albumin (g/dL)	$3.09 (\pm 0.58)$	
Blood Glucose (mg/dL)	194.72 (±94.60)	
Respiratory status	` ,	
Temperature (°C)	$37.39 (\pm 1.73)$	
Mechanical ventilation	36 (76.59%)	
Nasal-cannula oxygen	11 (23.40%)	
Intubated time (days)	12.38 (±7.14)	
P_aO_2 (mmhg)	74.01 (±24.63)	
Venous saturation (S _v O ₂)	67.58 (±25.34)	
$P_aO_2/FiO_2^{\#}$	159.69 (±90.84)	
A-a O ₂ Gradient Value [#]	283.22 (±208.31)	
Respiratory Rate (mov/min)	26.55 (±6.80)	
Histopathological findings	` ,	
Fibrosis (% of area)	30.00 (±12.68)	
Organizing Pneumonia (% of area)	10.74 (±14.89)	
Acute Fibrinous and Organizing Pneumonia (% of area)	6.91 (±12.49)	
Diffuse Alveolar Damage (% of area)	17.87 (±21.05)	
Pneumonitis (% of area)	22.57 (±15.34)	
Pulmonary infarction (% of area)	3.404 (±9.618)	

^{*} Fisher's exact test

^{**} t-Test

[#] Data after 18 days of hospitalization

Table 2.	COVID-19	patient chara	cteristics
----------	----------	---------------	------------

Table 2. COVID-19 patient characteristics Demographic Characteristics	Cluster 1	Cluster 2	P value
Domographic Characteristics	Mean (±SD) or	Mean (±SD) or	1 value
	N (%)	N (%)	
N	16	31	-
Sex			
Female	6 (37.50%)	17 (54.83%)	0.358*
Male	10 (62.50%)	14 (45.16%)	
Age (years)	70.81 (±10.34)	66.5 (±17.46)	0.369**
Illness Time (days)	12.06 (±6.97)	21.19 (±9.64)	0.001**
ICU Comorbi	11 (68.75%)	25 (80.64%)	0.471*
Hypertension	10 (62.50%)	16 (51.61%)	0.546*
BMI	28.39 (±6.92)	33.21 (±8.52)	0.057**
Diabetes	7 (43.75%)	11 (35.48%)	0.999*
History of smoking	4 (25.00%)	8 (25.80%)	0.999*
Heart disease	4 (25.00%)	8 (25.80%)	0.999*
Lung disease	3 (18.75%)	9 (29.03%)	0.505*
Kidney disease	1 (6.25%)	6 (19.35%)	0.395*
History of stroke	3 (18.75%)	4 (12.90%)	0.675*
Autoimmune diseases	1 (6.25%)	1 (3.22%)	0.999*
Laboratoria			
CRP (mg/dL)	11.54 (±1.64)	11.32 (±9.15)	0.924**
D-Dimers (µg/mL)	6.07 (±5.45)	4.38 (±3.91)	0.227**
LDH (mmol/L)	6.17 (±6.42)	4.41 (±4.52)	0.280**
Creatinine (mg/dL)	2.41 (±1.64)	2.12 (±1.21)	0.494**
Urea (mg/dL)	108.36 (±53.92)	125.09 (±60.75)	0.358**
AST (IU/L)	110.65 (±112.67) 72.40 (±59.92)	101.08 (±78.69) 71.98 (±53.88)	0.735** 0.980**
ALT (IU/L) AST/ALT	$2.1 (\pm 2.47)$	$1.6(\pm 0.92)$	0.319**
PT (INR)	$1.56 (\pm 0.98)$	$1.95 (\pm 2.55)$	0.560**
Albumin (g/dL)	3.24 (±0.65)	$3.01 (\pm 0.54)$	0.251**
Blood Glucose (mg/dL)	191.00 (±100.25)	196.65 (±96.32)	0.851**
Platelets $(10^3/\mu l)$	173.70 (±97.83)	273.10 (±128.20)	0.010**
Respirator	` ,	, ,	
Temperature (°C)	37.74 (±1.82)	37.20 (±1.62)	0.304**
Mechanical ventilation	11 (68.75%)	25 (80.64%)	0.471*
Nasal-cannula oxygen	5 (31.25%)	6 (19.35%)	0.471*
Intubated time (days)	8 (±4.72)	14.32 (±6.94)	0.009**
P_aO_2 (mmhg)	$75.54 (\pm 8.06)$	$73.27 (\pm 1.69)$	0.135**
Venous saturation (S_vO_2)	61.33 (±27.83)	70.59 (±19.27)	0.187**
P _a O ₂ /FiO ₂ #	216.16 (±32.94)	164.15 (±21.09)	<0.001**
A-a O ₂ Gradient Value [#]	40.20 (±101.48)	237.58 (±68.05) 26.45 (±5.75)	0.006**
Respiratory Rate (mov/min) PEEP	26.76 (±7.86)	, ,	0.878** 0.9611**
Histopathological findings, vascular st	9.63 (±5.08)	9.62 (±4.86)	0.9611**
Fibrosis (% of area)	24.38 (±11.59)	32.90 (±14.05)	0.042**
Organizing Pneumonia (% of area)	23.30 (±18.16)	24.50 (±15.71)	0.815**
Acute Fibrinous and Organizing Pneumonia (% of area)	18.33 (±12.24)	23.89 (±15.76)	0.225**
Diffuse Alveolar Damage (% of area)	34.00 (±24.03)	33.33 (±20.23)	0.920**
Pneumonitis (% of area)	20.67 (±18.52)	23.86 (±15.88)	0.540**
Pulmonary infarction (% of area)	26.67 (±14.14)	20.00 (±14.14)	0.132**
Disseminated Intravascular Coagulation	8 (50.00%)	5 (16.13%)	0.0198*
NLRP3 puncta per parenchyma area (mm²)	143.67 (±89.00)	238.40 (±157.76)	0.031**
Clearance Creatinine	32.94 (±22.95)	47.50 (±43.51)	0.4380**
MDRD GFR	41.58 (±30.03)	44.15 (±36.90)	0.9381**
Anticoagulation dose (mg) used close to death	14.68 (±10.07)	9.85 (±8.97)	0.0125**
Glasgow scale	$7.18 (\pm 5.70)$	6.61 (±5.23)	0.7280**
SOFA score	$7.12 (\pm 2.30)$	7.25 (±2.59)	0.6828**
MELD score	49.15 (±21.88)	50.91 (±40.97)	0.8113**
MODS	10.57 (±3.45)	10.39 (±3.16)	0.9946**

^{*} Fisher's exact test

^{**} t-Test

[#] Data after 18 days of hospitalization

Table 3. Radiological Analyzes

	Cluster 1	Cluster 2	P value
Initial CXR pattern			
No opacities	1 (6.250%)	3 (9.67%)	0.9101
Mild viral pneumonia	2 (12.50%)	3 (9.67%)	
Moderate viral pneumonia	8 (50.00%)	12 (38.70%)	
Severe viral pneumonia	5 (31.25%)	11 (35.48%)	
Impaired analysis	0	2 (6.45%)	
Last CXR pattern			
No opacities	1 (6.25%)	2 (6.45%)	0.9971
Mild viral pneumonia	3 (18.75%)	5 (16.12%)	
Moderate viral pneumonia	6 (37.50%)	12 (38.70%)	
Severe viral pneumonia	4 (25.00%)	8 (25.80%)	
Impaired analysis	2 (12.50%)	4 (12.90%)	
Imaging evolution until			
death	5 (22 220/)	10 (22 250/)	0.0264
Improvement (fewer opacities)	5 (33.33%)	10 (32.25%)	0.0364
Stability Warraning (many analities)	7 (46.66%)	4 (12.90%)	
Worsening (more opacities)	2 (13.33%)	12 (38.70%)	
Impaired analysis	1 (6.66%)	5 (16.12%)	
Disease Extent (Thoracic			
CT)			
0	0	0	0.0363
<25%	4 (66.66%)	1 (12.50%)	
25-50%	0	3 (37.50%)	
50-75%	1 (16.66%)	3 (37.50%)	
>75%	1 (16.66%)	1 (12.50%)	

Table 4. Characteristics of COVID-19 patients who were Demographics Characteristics	MV+	MV-	p value
Demographics Characteristics	Mean (±SD) or	Mean (±SD) or	p varue
	n (%)	n (%)	
N	36	11	
Sex	50	• •	
Female	17 (47.22%)	6 (54.54%)	0.7400*
Male	19 (52.77%)	5 (45.45%)	0.7400*
Age (years)	65.61 (±13.52)	75.72 (±17.61)	0.0493**
Illness Time (days)	20.94 (±10.76)	8.72 (±5.40)	0.0007**
ICU	36 (100.00%)	0 (0.00%)	>0.9999*
Comorbio	dities		
Hypertension	23 (63.88%)	3 (27.27%)	0.0433*
BMI	30.61 (±8.52)	34.56 (±14.46)	0.4324**
Diabetes	16 (44.44%)	2 (18.18%)	0.1644*
History of smoking	11 (30.55%)	3 (27.77%)	>0.9999*
Heart disease	11 (30.55%)	1 (9.09%)	0.2440*
Lung disease	9 (25.00%)	2 (18.18%)	>0.9999*
Kidney disease	6 (16.66%)	1 (9.09%)	>0.9999*
History of stroke	4 (11.11%)	3 (27.77%)	0.3296*
Autoimmune diseases	1 (2.77%)	1 (9.09%)	0.4172*
Laboratorial	findings		
CRP (mg/dL)	9.99 (±7.83)	16.02 (±9.29)	0.0377**
D-Dimers (µg/mL)	$4.99 (\pm 4.68)$	4.56 (±3.62)	0.7989**
LDH (mmol/L)	$5.78 (\pm 5.76)$	2.49 (±1.13)	0.0680**
Creatinine (mg/dL)	$1.58 (\pm 1.39)$	$1.05~(\pm 0.50)$	0.2242**
Urea (mg/dL)	138.18 (±54.07)	64.48 (±34.12)	0.0001**
AST (IU/L)	109.61 (±98.16)	84.81 (±54.14)	0.4725**
ALT (IU/L)	79.02 (±58.67)	45.38 (±26.97)	0.1254**
AST/ALT	$1.6 (\pm 1.74)$	$2.2~(\pm 0.88)$	0.3542**
PT (INR)	$1.53 (\pm 0.91)$	2.82 (±4.24)	0.0900**
Albumin (g/dL)	2.99 (±0.54)	3.78 (±0.41)	0.0034**
Blood Glucose (mg/dL)	198.22 (±93.77)	181.11 (±102.34)	0.6340**
Respiratory		2500(1.1.20)	0.000044
Temperature (°C)	37.51 (±1.79)	36.99 (±1.53)	0.3890**
P_aO_2 (mmhg)	79.57 (±20.19)	53.99 (±24.12)	0.0014**
Venous saturation (S _v O ₂)	70.86 (±14.36)	50.71 (±31.26)	0.0092**
P _a O ₂ /FiO ₂ #	132.63 (±67.94)	257.11 (±114.86)	
A-a O ₂ Gradient Value [#]	351.09 (±183.40)	45.69 (±26.55)	<0.0001**
Respiratory Rate (mov/min)	27.61 (±6.17)	23.09 (±7.89)	0.0669**
Histopathologic		20.00 (+12.21)	0.0015**
Fibrosis (% of area)	30.28 (±14.05)	29.09 (±12.21)	0.8015**
Organizing Pneumonia (% of area)	26.11 (±13.56)	20.00 (±11.54)	0.4520**
Acute Fibrinous and Organizing Pneumonia (% of area)	19.50 (±12.48)	26.00 (±15.16)	0.3906**
Diffuse Alveolar Damage (% of area)	28.82 (±19.34)	43.75 (±16.85)	0.0742**
Pneumonitis (% of area)	23.52 (±17.33)	20.00 (±8.16)	0.5435**
Pulmonary infarction (% of area)	25.00 (±10.00)	$10.00~(\pm 0.00)$	0.2235**
Inflammasome		204.0 (+156.6)	0.0210**
	204.3 (±155.5)	204.0 (±156.6)	0.9310**
NLRP3 puncta per parenchyma area (mm²)		267 2 (1122 1)	0.4106**
ASC puncta per parenchyma area (mm²) * Fisher's exact test	251.8 (±192.5)	267.3 (±133.1)	0.4196**

[#] data after 18 days of hospitalization

Figures and Figure Legends

Fig. 1. Sá et al.

849

851

852

853

854

855

856




Figure 1. Macrophages and endothelial cells contribute to inflammasome activation in the lungs of COVID-19 patients. Multiphoton microscopy analysis of lung autopsies of 47 COVID-19 patients and 5 uninfected controls (benign area of the lungs from adenocarcinoma patients). Images of ASC (A-D) or NLRP3 (E-H) puncta (red, indicated by white arrows) in CD64⁺ (in green; A, E), CD34⁺ (in purple; B, F), PDPN⁺ (in green; C, G) and SFTPC⁺ (in green; D, H) cells from a lung autopsy of a COVID-19 patient. DAPI stains cell nuclei

(blue). Scale bars 10 μm. The images were acquired by multiphoton microscopy using a 63x oil immersion objective and analyzed using ImageJ Software. (I-P) percentage of macrophages (CD64⁺), endothelial cells (CD34⁺), type I pneumocytes (PDPN⁺), and type II pneumocytes (SFTPC⁺) containing ASC (I-L) or NLRP3 (M-P) puncta. Each dot in the figures represents the value obtained from each individual. P-values are described in the figures comparing the indicated groups, as determined by Mann–Whitney test. Data are represented as violin plots with median and quartiles.




Figure 2. Inflammasome activation positively correlates with disease time, and viral load inversely correlates with disease time. Spearman correlation of pulmonary viral load, inflammasome activation and illness time in 47 fatal

COVID-19 patients. (**A**) Correlation of viral N2 with illness time; (**B**) Correlation of viral E with illness time; (**C**) Correlation of NLRP3 puncta per parenchyma area with illness time; (**D**) Correlation of ASC puncta per parenchyma area with illness time; (**E**) Correlation of NLRP3 puncta per parenchyma area with PaO₂/FiO₂. r and P-values are indicated in the figures.




Figure 3. Pulmonary viral load and inflammatory gene expression define two patient clusters in lethal cases of COVID-19. (A) Heatmap of the mRNA expression of inflammasomes, inflammatory molecules/cytokines and viral N2 and E in lung autopsies of 47 COVID-19 patients. PaO_2/FiO_2 (B) and A-a O_2 gradient (C) during disease development of patients from Cluster 1 (N=16, green) and Cluster 2 (N=31, red). *, P < 0.05 comparing the indicated groups, as determined by Area Under Curve test. (D-H) Analysis of Cluster 1 and Cluster 2 for illness time (D), PaO_2/FiO_2 (E), A-a O_2 gradient (F), fibrosis (G),

and NLRP3 puncta per lung parenchyma area (**H**). Each dot in the figure represents the value obtained from each individual. P-values are described in the figures comparing the indicated groups, as determined by Mann–Whitney test. Data are represented as violin plots with median and quartiles. (**I-J**) Representative H&E images of lung parenchyma of 3 patients of cluster 1 (**I**) and 3 patients of cluster 2 (**J**). Scale bars 200 µm.




Figure 4. COVID-19 patients from Cluster 1 contain higher viral loads in the lungs than patients from Cluster 2. Quantification of viral N2 (A) and E (B) in lung autopsies of 47 COVID-19 patients from Cluster 1 (N=16) and

Cluster 2 (N=31). (**C**) Quantification of the percentage of area stained for viral Spike protein in lung autopsies. Each dot in the figure represents the value obtained from each individual. P-values are described in the figures comparing the indicated groups, as determined by Mann–Whitney test. Data are represented as violin plots with median and quartiles. (**D-E**) Representative images of lung tissues stained for Spike (red) and Hematoxylin (blue). Scale bars 100 μ m.




Figure 5. Fibrosis is increased in cluster 2 patients. (**A-B**) Histopathological analysis of pulmonary samples from Cluster 1 and Cluster 2 for the presence of fibrosis (**A**) and Disseminated Intravascular Coagulation (**B**). (**C**) Platelet counts by laboratory analyses of blood samples from COVID-19 patients on the last


day of hospitalization. (**D**) Volcano plot analysis showing expression of fibrosis-related genes in lung autopsy of COVID-19 patients. Each dot in this figure represents a gene (average gene expression of 47 patient samples). Fold change Cluster 2/Cluster 1). The genes with statistically significant differences are indicated in color dots: *Plg* (**E**), *Plat* (**F**), *Plau* (**G**), *Ccr2* (**H**), *Ccl3* (**I**), *Cdkna1* (**J**), *Serpina1* (**K**), *Timp2* (**L**), and *Fgf1* (**M**). Each dot in the figures (**A**, **C**, **E-M**) represents the value obtained from each individual. P-values are described in the figures comparing the indicated groups, as determined by Mann–Whitney test. Data are represented as violin plots with median and quartiles. (**N-O**) Representative images of Masson-Goldner staining of lung parenchyma from three Cluster 1 patients (**N**) and three Cluster 2 patients (**O**). Shown are Nuclei (dark brown to black), Collagen (green/blue), Erythrocytes (bright red). Scale bars 200μm.

Supplementary Table 1.

Supplementary Table 1. The list of primer sequences for real time-PCR

Sequence of primer (5'- 3')
F: GGACTGAAGCACCTGTTGTGCA
R: TCCTGAGTCTCCCAAGGCATTC
F: TGTATGTGACTGCCCAAGATGAAG
R: AGAGGAGGTTGGTCTCACTACC
F: ATGGAGGGAAGATGTGCCTGTC
R: GTCCTGCTTTCTGTTCTCGCTC
F: AGGTCCCACAACTCGTCAAGCT
R: TGCTCACACGATTTCCCGCCAA
F: AGCTCACCGCTAACGTGCTGC
R: GCTTGGCTGCCGACTGAGGAG
F: ATTGAGGGCAGGCACAGAT
R: CTCCTTCAGGTTTCTGGTGACC
F: GCTGAGGTTGACATCACAGGCA
R: TGCTGTCAGAGGTCTTGTGCTC
F: GCTGCACCAAAAGTCTCTCCTC
R: CTGCTTGCCTTCTTGGGTCTCA
F: AGACAGCCACTCACCTCTTCAG
R: TTCTGCCAGTGCCTCTTTGCTG
F: GTCTCCTCTGACTTCAACAGCG
R: ACCACCCTGTTGCTGTAGCCAA
F: CTCTTCTGCCTGCTGCACTTTG
R: ATGGGCTACAGGCTTGTCACTC
F: TCTCCGAGATGCCTTCAGCAGA
R: TCAGACAAGGCTTGGCAACCCA
F: CCACAGACCTTCCAGGAGAATG
R: GTGCAGTTCAGTGATCGTACAGG
F: GATAGCCAGCCTAGAGGTATGG
R: CCTTGATGTTATCAGGAGGATTCA
F: GGGATGAAGGAGCTACTTGAGG
R: CCAAGAATGTGCTGTCAGAGGAC
F: CGGACTGTGATGGTCAACCTGA
R: GCACTTTGCCTCCCAGATCACA
F: GAGTGTGGAGACCATCAAGGAAG
R: TGCTTTGCGTTGGACATTCAAGTC
F: CTTGGATTCCTACAAAGAAGCAGC
R: TCCTCCTTCTGGAACTGCTGCA
F: AGAAGGCTCCAGCCATCTCTGT
R: TGCTGGTAGAGTTCGGTGCAGA
F: CCGTAACAGACATCTTTGCTGCC
R: GAGTGTCCTTCTCATGGTGGCT


Supplementary Figures and Supplementary Figure Legends



Supplementary Fig. 1. Histopathological patterns and inflammasome activation in lung autopsy of COVID-19 patients. Histopathological analysis of lethal cases of COVID-19 patients. (A) Proportion of lung parenchyma area (loss of airspace) of COVID-19 patients and uninfected controls (benign area of the lungs from adenocarcinoma patients). (B-C) Representative images of H&E stain showing the lung parenchyma. Scale bars 200 µm. (D-G) Multiphoton microscopy analysis of lung autopsies of 47 COVID-19 patients and 5

uninfected controls. Tissues were stained with anti-ASC (**D**, **E**) or anti-NLRP3 (**F**, **G**) for quantification of cells with inflammasome puncta in lung autopsies (in red, indicated by white arrows). DAPI stains cell nuclei (blue). Insets indicate a higher magnification of the indicated region (red rectangle). Scale bars 20 μm. (**H**) Percentage of NLRP3 puncta colocalizing with ASC puncta in the lungs of five COVID-19 patients. (**I**) Representative images showing ASC (green) and NLRP3 (red) colocalization. Scale bar 10 μm. Each dot in the figure represents the value obtained from each individual. P-values are shown in the figures comparing the indicated groups, as determined by Mann–Whitney test. Data are represented as violin plots with median and quartiles. The images were acquired by multiphoton microscope using a 63x oil immersion objective and analyzed using ImageJ Software.

Supplementary Fig. 2. Sá et al.



Supplementary Fig. 2. Total numbers of macrophages, endothelial cells, and type I and II pneumocytes are similar in the lungs of COVID-19 patients and uninfected controls. Multiphoton microscopy analysis of lung autopsies of 47 COVID-19 patients and 5 uninfected controls (benign area of the lungs from adenocarcinoma patients). (A-D) Numbers of macrophages (CD64+, A), endothelial cells (CD34+, B), type I pneumocytes (PDPN+, C) and type II pneumocytes (SFTPC+, D) per lung parenchyma area. Each dot in the figures represents the value obtained from each individual. P-values are shown in the figures comparing the indicated groups, as determined by Mann–Whitney test. Data are represented as violin plots with median and quartiles.

Supplementary Fig. 3. Sá et al.

957

959

960

961

962

963

964

965


966

967

968


969

970




Supplementary Fig. 3. Immunohistochemistry analysis of lung autopsies of patients with COVID-19 and uninfected controls. Immunohistochemistry analysis of lung autopsies of 47 COVID-19 patients and 5 uninfected controls (benign area of the lungs from adenocarcinoma patients). Quantification of the percentage of area stained for ASC (A), NLRP3 (B), cleaved GSDMD (C), IL-1β (**D**) and Caspase-1 (**E**). Each dot in the figures represents the value obtained from each individual. P-values are shown in the figures comparing the indicated groups, as determined by Mann-Whitney test. Data are represented as violin plots with median and quartiles. (F-H) Representative images of lungs from fatal cases of COVID-19, indicating colocalization of viral Spike, ASC, NLRP3, Caspase-1, IL-1β and cleaved GSDMD in endothelial cells (CD34⁺, **F**), macrophages (CD68⁺, **G**), and type II pneumocytes (SFTPC⁺, **H**).

Supplementary Fig. 4. Sá et al.



Supplementary Fig. 4. Non-significant correlation or viral loads and inflammasome activation in lethal cases of COVID-19 patients. Spearman correlation of pulmonary viral load and inflammasome activation in 47 fatal COVID-19 patients. (A) Correlation of viral N2 with NLRP3 puncta per parenchyma area; (B) Correlation of viral E with NLRP3 puncta per parenchyma area; (C) Correlation of viral N2 with ASC puncta per parenchyma area; (D) Correlation of viral E with ASC puncta per parenchyma area. r and p-value are indicated in the figure.



Supplementary Fig. 5. Gene expression in lungs of COVID-19 patients.

984

985

986

987

988

989

990

991

992


993

994

995

996

Correlation matrix of inflammasome and inflammatory gene expression in lung autopsy of 47 COVID-19 patients (A). Colors indicate correlation scores, categorized as positive strong correlation ($r \ge 0.70$; red); moderate positive correlation (0.50 \geq r \leq 0.70; orange); weak positive correlation (0.30 \geq r \leq 0.50; yellow); negative strong correlation ($r \ge -0.70$; dark blue); negative moderate correlation (-0.50 \geq r \leq -0.70; blue) or negative weak correlation (-0.30 \geq r \leq -0.50; light blue). Only correlations with p<0.05 are represented in the correlation matrix. (**B-U**) Expression of mRNA in the lung autopsies of COVID-19 patients and uninfected controls (benign area of the lungs from adenocarcinoma patients). Selected genes were II6 (B), II10 (C), II17 (D), Ifna1 (E), Ifnb1 (F), Ifna (G), II4 (H), II2 (I), Tnfa (J), II1a (K), II1b (L), II18 (M), I1ra (N), NIrp3 (O), NIrc4 (**P**), NIrp1 (**Q**), Aim2 (**R**), Pycard (**S**), Casp1 (**T**), Casp4 (**U**).



998

999

1000

1001

1002

1003

1004

Supplementary Fig. 6. CXR evolution of patients from Cluster 1 and Cluster 2. Analysis of the first and last Chest x-radiography (CXR) of 47 COVID-19 patients belonging from Cluster 1 (n=15) and Cluster 2 (n=31). (A) patients with reduced opacities (green), stability (blue) and increased opacities (red) comparing the fists and first CXR. Impaired analyses are shown in gray. Representative images of first and last CXR from two patients from Cluster 1, indicating stability in moderate and mild pneumonia (B) and two patients from Cluster 2, indicating worsening conditions in cases of severe pneumonia (**C**).